Prudential Financial
CARM

Prudential Financial’s Carisma Therapeutics CARM Stock Holding History

Prudential Financial’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-584
Closed -$7K – 2679
2022
Q1 		$7K Sell
584
-33,740
-98% -$471K ﹤0.01% 2598
2021
Q4 		$559K Buy
34,324
+33,685
+5,272% +$678K ﹤0.01% 2160
2021
Q3 		$10K Buy
639
+103
+19% +$4.94K ﹤0.01% 2581
2021
Q2 		$49K Buy
+536
New +$34.2K ﹤0.01% 2518

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Prudential Financial's CARM Position: Q2 2022 in Review

Prudential Financial sold out of Carisma Therapeutics (CARM) in Q2 2022, closing a stake of 584 shares — an estimated $7K sold.

Prudential Financial first reported a position in CARM in Q2 2021 and held it in 4 quarters. The position peaked at $559K in Q4 2021. 73 funds tracked by Wall St. Rank hold CARM as of Q2 2022.

  • Prudential Financial reported no remaining Carisma Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prudential Financial sold 584 Carisma Therapeutics shares in Q2 2022, an estimated $7K.
  • Prudential Financial first reported a position in Carisma Therapeutics in Q2 2021 and held it in 4 quarters.
  • Prudential Financial's Carisma Therapeutics position peaked at $559K in Q4 2021.
  • 73 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2022.

Based on Prudential Financial's 13F filing for Q2 2022, filed 15 Aug 2022.